Eyevensys
French tech company | Builders Republic
About
Clinical-stage biotech developing non-viral gene therapy for chronic eye diseases — using the EyePen electroporation device to deliver therapeutic genes directly into ocular tissue, targeting conditions such as glaucoma, age-related macular degeneration, and uveitis without viral vectors.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Extension
- Founded
- 2009
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 10 M€ raised since 2020
Funding rounds
- Extension — 2021
Investors
- Boehringer Ingelheim Venture Fund
- bpifrance
- Global Health Sciences Venture Fund
- Karista
- Korea Investment Partners
- Pontifax
- Pureos Bioventures
- Quark Venture
Notes
Renommée PulseSight Therapeutics.